Coldastop

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coldastop

Quick Facts

Property Description
Active ingredients Retinol (Vitamin A), alpha-Tocopherol (Vitamin E)
Form Nasal Oil (Topical Solution)
Pharmacological Class Epithelial regeneration stimulant, Antioxidant
General Purpose Mucosal restoration and lubrication
Origin Derived (Synthetic/Processed)

What Kind of Medicine is Coldastop?

Coldastop is defined as an oil-based mucosal restorative preparation, which is a combination product containing fat-soluble vitamins used topically. It is classified under the high-level pharmacological category of Epithelial regeneration stimulants and Antioxidants, positioning its therapeutic focus on tissue health rather than acting as a conventional decongestant. The product is frequently recognized for supporting the recovery of the nasal mucosa following injury or chronic dryness, providing regenerative support that differentiates it from simple saline lubricants. This preparation is typically available for over-the-counter access, supporting its role as a localized therapeutic agent.

Composition, Form, and Active Ingredients

The therapeutic profile of Coldastop relies on two essential nutrients, Retinol (Vitamin A) and alpha-Tocopherol (Vitamin E), delivered in an oil base as a Topical Solution. The Vitamin A component is supplied as the stable ester Retinyl Palmitate, while Vitamin E is typically present as alpha-Tocopherol Acetate. The use of a pharmaceutical-grade oil base is critical for dissolving these fat-soluble ingredients and for ensuring prolonged contact time with the nasal mucosa, which is a key feature of its delivery system. Vitamin A is necessary for the normal function of mucous membranes, involving cell differentiation and protection.

General Purpose and Core Benefits

The general purpose of Coldastop is to deliver focused regenerative support and protection to restore the integrity of the nasal mucosa. Vitamin A supports epithelialization, the process of generating new, healthy cells, while Vitamin E provides necessary antioxidant action, safeguarding cell membranes from damage caused by environmental factors. The preparation is intended to relieve symptoms such as irritation and dryness associated with rhinitis sicca (chronic nasal dryness), serving as a functional mucosal protectant.

What side effects are possible with Coldastop?

Possible side effects and safety information

The safety profile for Coldastop (Retinol Palmitate and alpha-Tocopherol Acetate) nasal oil is formally documented in government regulatory sources, classifying possible adverse reactions by the body system affected.

Official Adverse Reaction Classification

The frequency of most documented side effects, such as Headache, Nausea, Diarrhoea, Dizziness, and Rash, is officially categorized as Not known for the topical nasal formulation, meaning the frequency cannot be estimated from the available data. The documented reactions are grouped across several System-Organ Classes.

System-Organ Class Example Adverse Reaction Types
Immune System Potential for Anaphylaxis (a serious allergic reaction)
General & Administration Site Unusual tiredness or weakness
Gastrointestinal Nausea, Diarrhoea
Skin & Subcutaneous Tissue Rash, Allergic contact dermatitis

Safety Constraints and Special Populations

Official regulatory documents define specific limitations on the use of this preparation. The medicine is contraindicated (should not be used) in individuals with a known hypersensitivity or allergy to the active ingredients, any excipients, or to Peanut oil, which is contained in the formulation. Furthermore, the product must not be used in children under 3 years of age.

For women of childbearing age not using contraception, or during pregnancy, a maximum dose of 4 drops per day should not be exceeded. While the medicine is suitable for long-term treatment, general high-level safety concepts concerning its active vitamin ingredients caution against the systemic accumulation of Vitamin A at excessive doses.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of this oil-based preparation is associated with the systemic accumulation of its fat-soluble active ingredients, primarily Retinol (Vitamin A), a condition known as Hypervitaminosis. This risk applies especially to cases of excessive ingestion or absorption over long periods.

Documented Manifestations and Severe Outcomes

Official regulatory documents describe two toxicity patterns. Acute manifestations may include non-specific symptoms such as nausea, vomiting, severe headache, and dizziness. Chronic toxicity is associated with clinical signs like dry, cracked skin, alopecia (hair loss), fatigue, and bone/joint pain (arthralgia).

Life-threatening outcomes documented in the overdose profile include damage to the hepatic system (liver fibrosis or cirrhosis) and the neurological system, manifesting as increased intracranial pressure (pseudotumor cerebri). Furthermore, excessive systemic levels of alpha-Tocopherol (Vitamin E) may increase the risk of bleeding due to interference with blood clotting factors.

Emergency Response and Required Action

Regulatory guidance mandates that individuals seek immediate medical attention or contact emergency services if an overdose is suspected or if any signs of severe toxicity are present. The management strategy is officially defined as symptomatic and supportive treatment, with the primary intervention being the immediate discontinuation of the product. No specific antidote is known for this toxicity. Special consideration is noted for infants, children, and pregnant individuals, as these populations are cited as having specific, increased sensitivities to Retinol toxicity.

Therapeutic Uses of Coldastop

What Coldastop Treats: Main Uses and Benefits

Coldastop is commonly used across conditions presenting with persistent nasal dryness, which may include the chronic condition of rhinitis sicca. The Vitamin A component contributes to supporting the healthy state of the body's protective linings, including the nose.

The primary therapeutic benefit involves providing supportive assistance for the nasal lining, helping to ease the chronic irritation, burning, and tightness associated with noticeable physiological strain. This assistance may be relevant for managing symptoms that interfere with daily functioning. The medication is generally applied in settings where additional support for epithelial health is needed, such as in cases of nasal crusting and hardened secretions, recovery after nasal surgery, or damage linked to the excessive use of decongestants.

“This supportive action is relevant for easing the overall symptom burden linked to hardened material.”

The preparation supports a sense of stability during difficult episodes, and is applied in addressing symptoms that arise from mucosal atrophy.


Quick Fact: Symptom Categories

Focus Area Primary Symptom Relief
Chronic Conditions Rhinitis Sicca, Mucosal Atrophy
Acute Contexts Post-Surgical Support, Decongestant Damage
Symptoms Addressed Crusting, Irritation, Dryness

Eligibility and Restrictions for Use

Who can and cannot use Coldastop?

The eligibility for Coldastop Nasal Oil is strictly defined by official regulatory documents based on absolute prohibitions and restrictions related to its active ingredients and the age of the user.


Eligibility Scope

Classification Rule
Allowed Population Adults and children from 3 years of age.
Contraindicated Individuals with known hypersensitivity to the active ingredients (Retinol, alpha-Tocopherol) or excipients, including peanut and soy.
Age Exclusion Children under 3 years of age.

Reproductive Status Restrictions

Use is subject to a mandatory, dose-dependent prohibition concerning the Vitamin A content. The medicine is prohibited for pregnant women or women of childbearing potential without reliable contraception if the total daily dose exceeds the regulatory threshold of 10,000 I.E. (International Units) of Vitamin A. This restriction is formally established to manage risks associated with elevated Vitamin A levels. Conversely, the official labeling states that interruption of breastfeeding is not required. No specific restrictions based on renal or hepatic impairment are documented in the primary regulatory sources for this topical preparation.

The official regulatory documentation establishes mandatory user exclusions for safety and clearly defines the standard approved user population of adults and children starting from the minimum eligible age of three years.

What should I know about interactions with other medicines?

Official Interaction Restrictions

The official interaction profile of Coldastop is primarily governed by the systemic risks associated with its active ingredient, Retinol (Vitamin A). Co-administration with Tetracycline antibiotics (e.g., Doxycycline, Minocycline) is formally prohibited due to the documented risk of increased intracranial pressure (pseudotumor cerebri). A restriction also applies to the co-administration of the nasal oil with other systemic or topical retinoids (e.g., Acitretin, Tretinoin). This is a pharmacodynamic interaction that heightens the risk of additive systemic toxicity (hypervitaminosis A) and subsequent adverse effects. Furthermore, substances such as Mineral Oil, Cholestyramine, and Orlistat are documented to interfere with the absorption or clearance of Vitamin A, which may alter its overall systemic exposure. For local use, timing separation is noted as necessary when co-administering the oil-based nasal solution with other topical nasal preparations to prevent physical interference with their efficacy.


Population-Specific Cautions

Official documentation includes specific interaction notes for patients with underlying organ conditions. In patients with Hepatic Impairment, the documented risk of worsening liver problems is increased due to the Retinol component's systemic metabolic burden. Similarly, patients with Renal Impairment have a heightened risk of high blood levels of vitamin A due to impaired clearance, potentially increasing the severity of side effects.

Mechanism of Action

Gene Regulation and Epithelial Cell Regeneration

This core mechanism involves the active metabolite of Retinol (Vitamin A) acting as a ligand for nuclear receptors ( RARs/ RXRs). This binding event regulates gene transcription involved in cellular structure, initiating a cascade that drives the proliferation and proper differentiation of epithelial cells. This process leads to the cellular reorganization and maturation of the nasal mucosal barrier.


Molecular Protection through Antioxidant Scavenging

The alpha-Tocopherol (Vitamin E) component provides immediate cellular defense by incorporating into cell membranes to act as a non-enzymatic scavenger of Reactive Oxygen Species (ROS). By quenching these free radicals, it interrupts the destructive lipid peroxidation chain reaction, providing cellular defense that supports the integrity and function of existing and newly generated epithelial cells.


Synergistic Action and Physical Support

The mechanism operates via a dual-action synergy where the Vitamin A-driven process focuses on long-term regeneration, and the Vitamin E-driven process provides immediate protection. This is supported by the oil base, which ensures prolonged contact and provides a crucial physical lubrication mechanism that minimizes mechanical friction, supporting the cellular repair process.

Dosage and Administration Information

How Coldastop is Used

Coldastop is administered via the topical route as a nasal oil solution (nasal drops), which facilitates the localized delivery of its fat-soluble vitamin components to the nasal mucosa. This medicine is designed for use in an outpatient setting and is suitable for both adults and children from 3 years of age using the same regimen.


Dosing and Administration Protocol

the standard pattern of use involves applying 2 to 3 drops of the oil solution into each nostril. This procedure constitutes a single dose and is repeated multiple times a day, often specified as three times daily, to maintain contact with the nasal lining.

Usage Aspect Official Instruction
Route of Administration Topical (Intranasal Drops)
Standard Single Dose 2 to 3 drops per nostril
Frequency Pattern Multiple times per day (e.g., 3 times daily)
Duration of Use Suitable for long-term treatment; duration is not limited

Procedural Steps and Use Restrictions

Proper administration requires the user to tilt the head back when inserting the drops using the provided pipette. After the solution has been dropped into the nostrils, the user should gently press and massage the nasal wings from the outside to help distribute the oil across the mucosa.

A specific restriction on usage applies to women who are pregnant or of childbearing potential without reliable contraception. In this group, the maximum total daily dose must not exceed 4 drops per day across both nostrils combined.

Recent Clinical Evidence

Research evidence / Overview of studies for Coldastop

Evidence for use in Major Depressive Disorder (MDD)

Research exploring Coldastop for the treatment of Major Depressive Disorder (MDD) included several types of studies. Researchers conducted Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses to examine the drug in adults with MDD, including those with acute and previously treated forms of the condition. These studies explored how symptoms evolved in the observed populations, using standardized symptom severity scales (e.g., HAM-D and MADRS) and also evaluated outcomes reflecting daily functioning and quality of life (QoL). This research describes patterns observed over short-term and intermediate-term durations.

Studies reported measurements of symptom score evolution over defined time intervals, typically up to 6 months. Specifically, studies monitored outcomes related to response and remission in the observed populations compared to control groups. Studies examined changes measured during the study period, including outcomes reflecting daily functioning and quality of life. However, the evidence derived from these settings has sometimes noted heterogeneity when comparing results across different trials.

Long-term effects are not fully established. Follow-up durations were limited, typically not extending beyond 6 months.

Evidence for use in Generalized Anxiety Disorder (GAD)

Coldastop was also studied for Generalized Anxiety Disorder (GAD). Research explored short-term symptom changes in adults with GAD, including those with chronic manifestations of the condition. Studies primarily used Randomized Controlled Trials and pooled analyses to examine outcomes related to anxiety severity scores (HAM-A, GAD-7), functional impairment scores, and outcomes related to sleep quality. Findings report how symptoms evolved in the observed populations across short-term study durations, generally up to 8 to 12 weeks.

However, the evidence is limited, as the research primarily focused on short-term symptom changes. Long-term effects are not fully established, and the follow-up durations were limited, leaving uncertainty about patterns beyond a few months.

What is still uncertain about Coldastop

Studies help show what has been observed so far—and what is still uncertain. Data are still emerging, and certainty remains low in several areas. Long-term effects are not fully established, as follow-up durations were limited across the evidence base. Furthermore, some early studies had modest sample sizes, meaning that the evidence quality varies across studies. Comparative evidence is lacking in some areas, and the findings describe group patterns, not personal predictions.

Frequently Asked Questions (FAQ)

Common questions about Coldastop (FAQ)


Q: What is the official/regulatory purpose of Coldastop?

The medicine is approved for the localized treatment of the nasal mucosa. Its regulatory purpose is to help support the proper differentiation and regeneration of epithelial cells in the nasal lining, which is achieved through its active components.


Q: Is Coldastop classified as an anti-inflammatory or a pain reliever?

The primary function of Coldastop involves gene regulation to encourage cellular regeneration and antioxidant protection. According to its pharmacodynamic properties, it is not formally classified as a standard non-steroidal anti-inflammatory drug (NSAID) or a pain reliever.


Q: Is it true that Coldastop should be taken with food for better absorption?

Coldastop is administered topically, meaning it is applied directly into the nose as a nasal oil solution. Because the medicine bypasses the digestive system, its administration is generally considered independent of food intake, unlike some oral medications.


Q: What should be done with unused or expired Coldastop, based on disposal guidelines?

Unused or expired medicine should ideally be dropped off at a drug take-back location. If a program is unavailable, Regulatory guidance suggests mixing the oil with an undesirable substance, placing it in a sealed container, and disposing of it in household trash.


Q: What are the most common adverse effects associated with Coldastop, as listed in regulatory documents?

Official product information lists potential adverse reactions by body system, such as headache or gastrointestinal issues. However, the regulatory frequency for many of these effects is often officially categorized as 'Not known,' meaning a reliable rate cannot be estimated from the available data.


Q: Does Coldastop have a known tendency to cause drowsiness or fatigue?

Regulatory information has noted the possibility of general reactions such as dizziness or unusual tiredness. The official frequency of these potential effects is typically listed as unknown in the regulatory documents.


Q: What does the label say about combining Coldastop with alcohol?

Official regulatory guidance suggests discussing the use of this medicine with alcohol with a healthcare professional. This discussion is important given the potential for the Vitamin A component to contribute to the body's liver burden.


Q: Are there known interactions between Coldastop and common blood thinner medications?

Yes, the Vitamin A component can interact with certain anticoagulant, or 'blood thinner,' medications. Regulatory information typically specifies the need to inform a doctor or pharmacist of all medicines taken.


Q: What is the official information regarding interactions between Coldastop and herbal supplements?

Regulatory information generally advises caution with certain herbal supplements, especially those that may affect liver function. Official guidance emphasizes informing a healthcare professional of all supplements used to allow for assessment of interaction risk.


Q: What information is provided regarding the use of Coldastop while breastfeeding?

Official guidance for the use of Coldastop while breastfeeding relates to the systemic absorption of Vitamin A. Daily doses of Vitamin A exceeding 3,000 micrograms (10,000 IU) is advised to be avoided due to the documented potential for toxicity in the infant.


Q: Where can one find the primary research and evidence summaries for Coldastop?

Official clinical evidence summaries and detailed drug information are typically published by the regulatory agencies that approved the product, such as the EMA or FDA DailyMed. These sources contain summaries of clinical trial findings.


Q: Is Coldastop considered a controlled or scheduled substance?

This medicine is not classified as a controlled or scheduled substance by regulatory drug enforcement agencies. It is regulated as a prescription-only or pharmacy-only medicine based on local laws.


Q: Is Coldastop a type of steroid medication?

No, the active ingredients in Coldastop are Vitamin A (Retinol Palmitate) and Vitamin E (alpha-Tocopherol Acetate). It is not a steroid medication, which is a separate class of drugs.


Q: Are there any known differences in how Coldastop may affect men versus women, based on clinical data?

Official documentation does include specific dosing restrictions for women of childbearing potential due to the systemic risks associated with the Vitamin A component. Otherwise, general clinical outcomes are usually reported for the study population as a whole.


Q: Does Coldastop interact with daily vitamins or mineral supplements?

Official product information cautions against taking Coldastop with other topical or systemic retinoids. This restriction is in place due to the potential for additive systemic toxicity, known as hypervitaminosis A.


Q: What is the general information about what happens if a dose of Coldastop is missed?

If a dose is missed, official patient information typically describes the protocol as taking the next scheduled dose as usual. Because the medicine involves vitamins, a single missed dose is generally not considered a cause for concern.


Q: Is there an official, patient-friendly information leaflet available for Coldastop?

Yes, a Patient Information Leaflet (PIL) or Medication Guide is provided with the product as required by regulatory authorities. This document contains essential instructions for use, side effects, and required storage conditions.


Q: Are there any warnings about taking Coldastop before driving or operating machinery?

Regulatory information advises caution if a patient experiences certain side effects, such as dizziness. If these reactions occur, the patient should be aware that their ability to drive or operate machinery may be affected.


Q: What is the significance of the specific dosage form (e.g., tablet, capsule) of Coldastop?

The nasal oil solution is designed specifically to ensure prolonged contact with the nasal mucosa. The oil base also provides physical lubrication while facilitating the localized delivery of the active vitamin components.

How should Coldastop be stored and disposed of?

The storage and disposal of Coldastop Nasal Oil must strictly follow the conditions defined in official regulatory documents to maintain its stability and integrity.

Required Storage Conditions

Constraint Regulatory Requirement
Temperature Do not store above 25 C (77 F).
Protection Store in the original packaging to ensure protection from light.
Handling Close the bottle well immediately after each use.
Child Safety Keep this medicine out of the sight and reach of children.

Stability and Disposal

The product is stable for only six weeks after the bottle is opened for the first time. The medicine must be discarded if stronger cloudiness or a change in smell is noticed, regardless of the expiry date.

Official disposal instructions prohibit discarding the oil in wastewater or household waste. Users are required to ask their pharmacist for guidance on how to properly dispose of unused or expired product according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coldastop found in:

A-Z Index: